In one paragraphArticle in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
4 authors.
Nahed JalloulNahed Jalloul, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ; Shridar Ganesan, MD, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ; Judy E. Garber, MD, Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Hossein Khiabanian, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.ORCID 0000-0002-8726-7060 Shridar GanesanNahed Jalloul, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ; Shridar Ganesan, MD, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ; Judy E. Garber, MD, Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Hossein Khiabanian, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.ORCID 0000-0002-5404-3044 Judy E GarberNahed Jalloul, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ; Shridar Ganesan, MD, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ; Judy E. Garber, MD, Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Hossein Khiabanian, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.
Hossein KhiabanianNahed Jalloul, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ; Shridar Ganesan, MD, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ; Judy E. Garber, MD, Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Hossein Khiabanian, PhD, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ.ORCID 0000-0003-1446-4394 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
What OpenQuestion holds
Textmetadata
Read underepoch 390